List of Signifor Lar Kit drug patents

Signifor Lar Kit is owned by Recordati Rare.

Signifor Lar Kit contains Pasireotide Pamoate.

Signifor Lar Kit has a total of 4 drug patents out of which 0 drug patents have expired.

Signifor Lar Kit was authorised for market use on 15 December, 2014.

Signifor Lar Kit is available in for suspension;intramuscular dosage forms.

Signifor Lar Kit can be used as method of treating acromegaly.

The generics of Signifor Lar Kit are possible to be released after 23 May, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7473761 RECORDATI RARE Somatostatin analogues
Dec, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8822637 RECORDATI RARE Somatostatin analogues
Aug, 2023

(5 months from now)

US7759308 RECORDATI RARE Microparticles comprising somatostatin analogues
Oct, 2026

(3 years from now)

US9351923 RECORDATI RARE Extended-release composition comprising a somatostatin derivative in microparticles
May, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 29, 2025

Drugs and Companies using PASIREOTIDE PAMOATE ingredient

Market Authorisation Date: 15 December, 2014

Treatment: Method of treating acromegaly

Dosage: FOR SUSPENSION;INTRAMUSCULAR

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in